课题基金 / 基金详情

Hippocampal Structure and Function in Cognitive Impairment

Hippocampal Structure and Function in Cognitive Impairment
认知障碍中的海马结构和功能
批准号:
8368503
负责人:
Geoffrey Allen Kerchner
金额:
$15.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-15 至 2017-07-31

项目摘要

项目成果

Geoffrey Allen Kerchner的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在此申请Paul B. Beeson老年患者导向研究职业发展奖,候选人寻求5年的薪水和研究支持,以获得培训并从事与神经影像学和临床前阿尔茨海默病(AD)相关的研究项目。长期目标是成为一名独立的研究者,并建立一个专门研究阿尔茨海默病和其他神经退行性疾病的实验室。具体的希望是使用先进的神经成像技术来创建新颖、敏感的生物标志物,用于早期AD诊断和疾病监测。尽管到目前为止他的训练有了很大的进步,但他的知识和技能仍然存在差距。旨在填补这些空白的短期目标包括:(1)扩展之前的7-特斯拉(7T)磁共振成像(MRI)培训;(2)培养设计、执行和解释功能磁共振成像实验的新技能;(三)掌握临床流行病学和统计学的新技能;(4)巩固临床研究设计技能。与他的导师团队一起,他制定了一个全面的培训计划,其中包括以下概述的研究项目、课程作业以及与导师的定期会议。他在该提案中的总体目标是开发在该奖项的第4-5年期间提交成功的RO1申请所需的技能和初步数据。
英文摘要
DESCRIPTION (provided by applicant): In this application for a Paul B. Beeson Patient-Oriented Research Career Development Award in Aging, the candidate seeks 5 years of salary and research support to obtain training and to pursue a research project related to neuroimaging and preclinical Alzheimer's disease (AD). The long term goal is to become an independent investigator and to establish a laboratory dedicated to the study of AD and other neurodegenerative diseases. The specific hope is to use advanced neuroimaging technologies to create novel, sensitive biomarkers for early AD diagnosis and disease monitoring. Despite substantial progress in his training so far, gaps remain in his knowledge and skills. Short term goals, aimed at filling these gaps, include: (1) to expand upon previous training in 7-Tesla (7T) magnetic resonance imaging (MRI); (2) to develop new skills in designing, performing, and interpreting fMRI experiments; (3) to achieve new skills in clinical epidemiology and statistics; and (4) to solidify skills in clinical research design. With his mentorship team, he has developed a comprehensive training program, which includes the research project outlined below, coursework, and regular meetings with his mentors. His overall goal in this proposal is to develop the skills and preliminary data needed to submit a successful RO1 application during Years 4-5 of the award. The proposed research seeks to fill a critical need for biomarkers that can detect the earliest, preclinical signs of AD, during a period of amnestic Mild Cognitive Impairment (aMCI). Such biomarkers may facilitate the eventual delivery of novel disease-modifying therapeutics to the minimally affected patients who stand the most to benefit. Neuroimaging holds great promise, but conventional technologies are insensitive to early disease. Post-mortem studies reveal that specific subfields of the hippocampus, including the CA1 apical neuropil, develop pathology around the time that patients begin to experience early memory impairment. Therefore, to be maximally sensitive to early disease, neuroimaging biomarkers should be able to assay the integrity of focal hippocampal subfield areas. Here, the candidate proposes to apply two complementary, highresolution, advanced imaging technologies to the problem: (1) 7T MRI, which can reveal hippocampal microstructure at ~200 ¿m resolution; and (2) high-resolution 3T fMRI coupled with an event-related face-name pairing task, to study patterns of hippocampal subfield activation that correlate with remembering or forgetting. He will assemble cohorts of 30 patients with aMCI and 30 age-matched normal controls, and in Aim 1 will use the neuroimaging tools to discover the structural and functional correlates of memory impairment. He will follow subjects annually (average span 40 months), and in Aim 2 will identify the baseline structural and functional imaging metrics that are most predictive of subsequent cognitive decline. In addition to contributing to preclinical AD biomarker development, this work promises to reveal basic details of the structural and functional underpinnings of hippocampal-dependent memory loss in aMCI and AD. PUBLIC HEALTH RELEVANCE: Alzheimer's disease is epidemic. In addition to the need for new treatments that can stop or slow the disease, there is a parallel need for biomarkers capable of identifying the illness in its earliest possible stages, in order to facilitate the evenual delivery of new treatments to patients with the most to lose. The proposed work focuses on two advanced neuroimaging technologies that may help to fill this critical gap.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hippocampal Structure and Function in Cognitive Impairment
  • 批准号:
    8529445
  • 项目类别:
  • 资助金额:
    $15.62万
  • 财政年份:
    2012
  • 负责人:
    Geoffrey Allen Kerchner
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: